149 related articles for article (PubMed ID: 9873591)
1. Mechanism based representation of the active site of 5 alpha-reductase (5AR).
Ahmed S; Denison S
Bioorg Med Chem Lett; 1998 Sep; 8(18):2615-70. PubMed ID: 9873591
[TBL] [Abstract][Full Text] [Related]
2. The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.
Li X; Chen C; Singh SM; Labrie F; Labire F [corrected to Labrie F]
Steroids; 1995 Jun; 60(6):430-41. PubMed ID: 7676475
[TBL] [Abstract][Full Text] [Related]
3. Steroidal 5α-Reductase Inhibitors: A Comparative 3D-QSAR Study Review.
Thareja S
Chem Rev; 2015 Apr; 115(8):2883-94. PubMed ID: 25785489
[No Abstract] [Full Text] [Related]
4. Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids.
Tian G; Haffner CD
J Biol Chem; 2001 Jun; 276(24):21359-64. PubMed ID: 11279132
[TBL] [Abstract][Full Text] [Related]
5. Kinetic mechanism of reduction of testosterone by hepatic 5 beta-reductase of chicken and inhibition of the reductase activity by a secosteroid, an azasteroid and glycyrrhetinic acid.
Yoshida M; Kuroki Y; Kobayashi E; Tamaoki B
J Steroid Biochem Mol Biol; 1992 Jan; 41(1):29-36. PubMed ID: 1734934
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
7. Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids.
Thareja S; Rajpoot T; Verma SK
Steroids; 2015 Mar; 95():96-103. PubMed ID: 25582615
[TBL] [Abstract][Full Text] [Related]
8. Substrate interaction with 5alpha-reductase enzyme: influence of the 17beta-chain chirality in the mechanism of action of 4-azasteroid inhibitors.
Grisenti P; Magni A; Olgiati V; Manzocchi A; Ferraboschi P; Villani V; Pucciariello R; Celotti F
Steroids; 2001 Nov; 66(11):803-10. PubMed ID: 11576619
[TBL] [Abstract][Full Text] [Related]
9. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
10. In vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5 alpha-reductase and comparison of two inhibitors.
Toomey RE; Goode RL; Petrow V; Neubauer BL
Prostate; 1991; 19(1):63-72. PubMed ID: 1876537
[TBL] [Abstract][Full Text] [Related]
11. Biological activities of a new steroidal inhibitor of delta 4-5 alpha-reductase.
Brooks JR; Berman C; Hichens M; Primka RL; Reynolds GF; Rasmusson GH
Proc Soc Exp Biol Med; 1982 Jan; 169(1):67-73. PubMed ID: 7063497
[No Abstract] [Full Text] [Related]
12. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
13. Determination of rat 5alpha-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines.
Szécsi M; Ondré D; Tóth I; Magony S; Wölfling J; Schneider G; Julesz J
Acta Biol Hung; 2010 Sep; 61(3):274-81. PubMed ID: 20724274
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic-like properties of 5-alpha-reductase inhibitors.
Bortolato M; Frau R; Orrù M; Bourov Y; Marrosu F; Mereu G; Devoto P; Gessa GL
Neuropsychopharmacology; 2008 Dec; 33(13):3146-56. PubMed ID: 18354385
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of steroidogenic enzymes metabolizing testosterone or dihydrotestosterone by human chorionic gonadotropin in cultured rat neonatal interstitial cells.
Murono EP
Acta Endocrinol (Copenh); 1990 Mar; 122(3):289-95. PubMed ID: 2158194
[TBL] [Abstract][Full Text] [Related]
16. The human keratinocyte cell line HaCaT: an in vitro cell culture model for keratinocyte testosterone metabolism.
Altenburger R; Kissel T
Pharm Res; 1999 May; 16(5):766-71. PubMed ID: 10350023
[No Abstract] [Full Text] [Related]
17. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
Tian G; Mook RA; Moss ML; Frye SV
Biochemistry; 1995 Oct; 34(41):13453-9. PubMed ID: 7577933
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
Frye SV; Haffner CD; Maloney PR; Hiner RN; Dorsey GF; Noe RA; Unwalla RJ; Batchelor KW; Bramson HN; Stuart JD
J Med Chem; 1995 Jul; 38(14):2621-7. PubMed ID: 7629802
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells.
Délos S; Iehlé C; Martin PM; Raynaud JP
J Steroid Biochem Mol Biol; 1994 Mar; 48(4):347-52. PubMed ID: 8142312
[TBL] [Abstract][Full Text] [Related]
20. Effects of the anti-androgen finasteride on the modulatory actions of oestradiol on androgen metabolism by human gingival fibroblasts.
Tilakaratne A; Soory M
Arch Oral Biol; 2001 Feb; 46(2):109-15. PubMed ID: 11163318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
